DNA and histone deacetylases as targets for neuroblastoma treatment

Auclair C. (1987). Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 259: 1-14.Search in Google Scholar

Bader P, Schilling F, Schlaud M, Girgert R, Handgretinger R, Klingebiel T, Treuner J, Liu C, Niethammer D and Beck JF. (1999). Expression analysis of multidrug resistance associated genes in neuroblastomas. Onco. Rep 6: 1143-1146.Search in Google Scholar

Bates SE, Shieh CY and Tsokos M. (1991). Expression of mdr-1/P-glycoprotein in human neuroblastoma. Am J Pathol 139: 305-315.Search in Google Scholar

Bedrnicek J, Vicha A, Jarosova M, Holzerova M, Cinatl J Jr, Michaelis M, Cinatl J and Eckschlager T. (2005). Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. Neoplasma. 52: 415-419.Search in Google Scholar

Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, Jonas D, Doerr HW and Cinatl J Jr. (2007). Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer 96: 1699-706.Search in Google Scholar

Bolden JE, Peart MJ and Johnstone RW. (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.Search in Google Scholar

Brodeur GM. (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.Search in Google Scholar

Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragno M and Boccuzzi G. (2006). Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191: 465-472.Search in Google Scholar

Chai G, Li L, Zhou W, Wu L, Zhao Y, Wang D, Lu S, Yu Y, Wang H, McNutt MA, Hu YG, Chen Y, Yang Y, Wu X, Otterson GA and Zhu WG. (2008). HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS ONE 3: e2445.Search in Google Scholar

Cinatl J Jr, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW and Kornhuber B. (1996). Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7: 766-773.Search in Google Scholar

de Cremoux P, Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, Schleiermacher G, Fehlbaum P, Doz F, Mosseri V, Delattre O, Klijanienko J, Vielh P and Michon J. Role of chemotherapy resistance genes in outcome of neuroblastoma. (2007). Pediatr Blood Cancer 48: 311-317.10.1002/pbc.2085316609945Search in Google Scholar

Emanuel SL, Chamberlin HA and Cohen D. (1999). Antimitotic drugs cause increased tumorigenicity of multidrug resistant cells. Int J Oncol 14: 487-494.Search in Google Scholar

Fossé P, René B, Charra M, Paoletti C and Saucier JM. (1992). Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol Pharmacol 42: 590-595.Search in Google Scholar

Froelich-Ammon SJ, Patchan MW, Osheroff N and Thompson RB. (1995). Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem 270: 4998-5004.Search in Google Scholar

Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A and Frühwald MC. (2007). Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120: 1787-1794.Search in Google Scholar

Gavelová M, Hladíková J, Vildová L, Novotná R, Vondrácek J, Krcmár P, Machala M and Skálová L. (2008). Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells. Chem Biol Interact 176: 9-18.Search in Google Scholar

Hopkins-Donaldson S, Yan P, Bourloud KB, Muhlethaler A, Bodmer JL and Gross N. (2002). Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells. Oncogene 21: 6132-37.Search in Google Scholar

Hooven LA, Mahadevan B, Keshava C, Johns C, Pereira C, Desai D, Amin S, Weston A and Baird WM. (2005). Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a] pyrene DNA adduct formation in human cells. Bioorg Med Chem Lett 15: 1283-128710.1016/j.bmcl.2005.01.03215713371Search in Google Scholar

Hřebačková J, Poljaková J, Eckschlager T, Hraběta J, Procházka P, Smutný S and Stiborová M. (2009). Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells. Interdisc Toxicol 2: 205-210.Search in Google Scholar

Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y and Carrier F. (2003). Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300.Search in Google Scholar

Klener P. (1996). Anticancer chemotherapy (in Czech) Galén, Praha.Search in Google Scholar

Kotchetkov R, Driever PH, Cinatl J, Michaelis M, Karaskova J, Blaheta R, Squire JA, Von Deimling A, Moog J and Cinatl J Jr. (2005). Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol 27: 1029-1037.Search in Google Scholar

Kucerova H, Sumerauer D, Drahokoupilova E, Piskova M, Bedrnicek J and Eckschlager T. (2001). Significance of P-glycoprotein expression in childhood malignant tumors. Neoplasma 48: 472-478.Search in Google Scholar

Kurowski C and Berthold F. (1998). Presence of classical multidrug resistance and P-glycoprotein expression in human neuroblastoma cells. Ann Oncol 9: 1009-1014.Search in Google Scholar

Lal S, Mahajan A, Chen WN and Chowbay B. (2010). Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 11: 115-128.Search in Google Scholar

Lara-Bohórquez C, González-Cámpora R, Mendoza-García E, Ríos-Martín JJ, Pareja-Megía MJ and López-Beltrán A. (2008). TP53, BCL-2, p21Waf1/Cip1 and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors. Anal. Quant Cytol Histol 30: 105-112.Search in Google Scholar

Marchion DC, Bicaku E, Daud AI, Sullivan DM and Munster PN. (2005a) Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65: 3815-3822.10.1158/0008-5472.CAN-04-247815867379Search in Google Scholar

Marchion DC, Bicaku E, Daud AI, Sullivan DM and Munster PN. (2005b) In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol. Cancer Ther 4: 1993-2000.10.1158/1535-7163.MCT-05-019416373714Search in Google Scholar

Maris JM and Matthay KK. (1999). Molecular biology of neuroblastoma. J Clin Oncol 17: 2264-2279.Search in Google Scholar

Maris JM, Hogarty MD, Bagatell R and Cohn SL. (2007). Neuroblastoma. Lancet 369: 2106-2120.Search in Google Scholar

Marks PA, Miller T and Richon VM. (2003). Histone deacetylases. Curr Opin Pharmacol 3: 344-351.Search in Google Scholar

Marks PA, Richon VM, Miller T and Kelly WK. (2004). Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168.Search in Google Scholar

Merk HF and Jugert FK. (1991). Cutaneous NAD(P)H: quinone reductase: a xenobiotica-metabolizing enzyme with potential cancer and oxidation stress-protecting properties. Skin Pharmacol 4 Suppl 1: 95-100.Search in Google Scholar

Michaelis M, Suhan T, Cinatl J, Driever PH and Cinatl J Jr. (2004). Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol 25: 1795-1799.Search in Google Scholar

Michaelis M, Doerr HW and Cinatl J Jr. (2007). Valproic acid as anti-cancer drug. Curr Pharm Des 13: 3378-3393.Search in Google Scholar

Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, Saucier JM, Charra M, Belehradek J Jr and Fermandjian S. (1991). DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 25: 1820-1829.Search in Google Scholar

Morgenstern BZ, Krivoshik AP, Rodriguez V and Anderson PM. (2004). Wilms' tumor and neuroblastoma. Acta Paediatr Suppl 93: 78-85.Search in Google Scholar

Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL and Haber M. (1996). Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334: 231-238.Search in Google Scholar

Oesch-Bartlmowicz B and Oesch F. (2004) Modulation of mutagenicity by phosphorylation of mutagen-metabolizing enzymes. Arch Biochem Biophys 423: 31-36.10.1016/j.abb.2003.11.02014989261Search in Google Scholar

Otter I, Conus S, Ravn U, Rager M, Olivier R, Monney L, Fabbro D and Borner C. (1998). The binding properties and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli. J Biol Chem 273: 6110-6120.Search in Google Scholar

Peaston AE, Gardaneh M, Franco AV, Hocker JE, Murphy KM, Farnsworth ML, Catchpoole DR, Haber M, Norris MD, Lock RB and Marshall GM. (2001). MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. Br J Cancer 85: 1564-1571.Search in Google Scholar

Poljaková J, Eckschlager T, Hřebačková J, Hraběta J and Stiborová M. (2008). The comparison of cytotoxicity of anticancer drug doxorubicin and ellipticine to human neuroblastoma cells. Interdisc Toxicol 1: 186-189.Search in Google Scholar

Poljakova J, Eckschlager T, Hrabeta J, Hrebackova J, Smutny S, Frei E, Martinek V, Kizek R and Stiborova M. (2009). The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol 77: 1466-1479.Search in Google Scholar

Santini V, Gozzini A and Ferrari G. (2007). Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 8: 383-393.Search in Google Scholar

Singh MP, Hill GC, Peoch D, Rayner B, Inabach JL and Lown JW. (1994). High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33: 10271-10285.Search in Google Scholar

Song X, Liu X, Chi W, Liu Y, Wei L, Wang X and Yu J. (2006). Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 58: 776-784.Search in Google Scholar

Stiborová M, Bieler CA, Wiessler M and Frei E. (2001). The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62: 675-684.Search in Google Scholar

Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M and Frei E. (2003a) DNA adduct formation by the anticancer drug ellipticine in rats determined by ³²P-postlabeling. Int J Cancer 107: 885-890.10.1002/ijc.1151114601046Search in Google Scholar

Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E. (2003b) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 16: 38-47.10.1021/tx020081812693029Search in Google Scholar

Stiborová M, Sejbal J, Bořek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudeček J, Wiessler M and Frei E. (2004). The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N²-oxide. Cancer Res 64: 8374-8380.Search in Google Scholar

Stiborová M, Rupertová M. Schmeiser HH and Frei E. (2006). Molecular mechanism of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150: 13-23.Search in Google Scholar

Stiborová M, Poljaková J, Ryšlavá H, Dračínský M, Eckschlager T and Frei E. (2007a) Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer 120: 243-251.10.1002/ijc.2224717066455Search in Google Scholar

Stiborová M, Rupertová M, Aimová D, Ryšlavá H and Frei E. (2007b) Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology 236: 50-60.10.1016/j.tox.2007.03.02617482743Search in Google Scholar

Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudeček J, Phillips DH and Frei E. (2008). Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH: cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol 226: 318-327.Search in Google Scholar

Stiborová M, Rupertová M and Frei E. (2010). Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its antitumor efficiency. Biochim Biophys Acta, in press.Search in Google Scholar

Schwab M. (1999). Human neuroblastoma: from basic science to clinical debut of cellular oncogenes. Naturwissenschaften 86: 71-78.Search in Google Scholar

Uccini S, Colarossi C, Scarpino S, Boldrini R, Natali PG, Nicotra MR, Perla FM, Mannarino O, Altavista P, Boglino C, Cappelli CA, Cozzi D, Donfrancesco A, Kokai G, Losty PD, McDowell HP and Dominici C. (2006). Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours. Br J Cancer 95: 49-5510.1038/sj.bjc.6603212236048716755292Search in Google Scholar

van Schaik R. (2005). Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 23: 513-522.Search in Google Scholar

van Schaik RH. (2008). CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 11: 77-9810.1016/j.drup.2008.03.00218486526Search in Google Scholar

Voigt A, Hartmann P and Zintl F. (2000). Differentiation, proliferation and adhesion of human neuroblastoma cells after treatment with retinoic acid. Cell Adhes Commun 7: 423-440.Search in Google Scholar

Wang H and Tompkins L. (2008). CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9: 598-610.Search in Google Scholar

Westermann F and Schwab M. (2002). Genetic parameters of neuroblastomas. Cancer Lett 184: 127-147.Search in Google Scholar

Witt O, Deubzer HE, Lodrini M, Milde T and Oehme I. (2009). Targeting histone deacetylases in neuroblastoma. Curr Pharm Des 15: 436-447.Search in Google Scholar

Zhu WG and Otterson GA. (2003). The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 3: 187-199.Search in Google Scholar